Market closedNon-fractional
Sutro Biopharma/STRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Sutro Biopharma
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Ticker
STRO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
300
Website
www.sutrobio.com
Sutro Biopharma Metrics
BasicAdvanced
$350M
Market cap
-
P/E ratio
-$1.89
EPS
1.09
Beta
-
Dividend rate
Price and volume
Market cap
$350M
Beta
1.09
Financial strength
Current ratio
4.46
Quick ratio
4.333
Long term debt to equity
21.828
Total debt to equity
28.636
Interest coverage (TTM)
-5.04%
Management effectiveness
Return on assets (TTM)
-17.01%
Return on equity (TTM)
-81.12%
Valuation
Price to revenue (TTM)
1.69
Price to book
2.72
Price to tangible book (TTM)
2.72
Price to free cash flow (TTM)
-2.185
Growth
Revenue change (TTM)
106.66%
Earnings per share change (TTM)
-21.91%
3-year revenue growth (CAGR)
45.29%
3-year earnings per share growth (CAGR)
18.99%
What the Analysts think about Sutro Biopharma
Analyst Ratings
Majority rating from 11 analysts.
Sutro Biopharma Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$13M
-88.57%
Net income
-$58M
-287.74%
Profit margin
-447.69%
-1,742.30%
Sutro Biopharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.64
-$0.81
$0.52
-$0.95
-
Expected
-$0.73
-$0.74
-$0.82
-$0.92
-$0.79
Surprise
-12.63%
10.05%
-163.16%
3.04%
-
Sutro Biopharma News
AllArticlesVideos
VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline
PRNewsWire·2 months ago
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
GlobeNewsWire·2 months ago
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sutro Biopharma stock?
Sutro Biopharma (STRO) has a market cap of $350M as of July 27, 2024.
What is the P/E ratio for Sutro Biopharma stock?
The price to earnings (P/E) ratio for Sutro Biopharma (STRO) stock is 0 as of July 27, 2024.
Does Sutro Biopharma stock pay dividends?
No, Sutro Biopharma (STRO) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Sutro Biopharma dividend payment date?
Sutro Biopharma (STRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Sutro Biopharma?
Sutro Biopharma (STRO) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Sutro Biopharma stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.